heart failure
Conditions
Interventions
Patients will be assigned to receive either 16 mg of tolvaptan sodium phosphate intravenously over 1 hour once daily or 15 mg of tolvaptan orally once daily for up to 7 days. Standard laboratory tests
Sponsors
Ohtani Hayato
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. patients between 20 and 80 years of age 2. systolic blood pressure greater than 100 mmHg and heart rate less than 100 beats/minute at the time of enrollment 3. patients who are taking 20 mg of furosemide and are not receiving intravenous diuretics 4. Patients whose consent to participate in this study has been obtained by signing a consent form by the patient or a substitute consenter.
Exclusion criteria
Exclusion criteria: 1. patients with cardiogenic shock (with continuous catecholamine administration and mechanical circulatory support) 2. patients with serum Na concentration less than 125 mEq/l or greater than 145 mEq/l 3. patients whose participation is deemed inappropriate by the attending physician 4. dialysis patients 5. patients who have difficulty with oral fluid intake
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of change in pulmonary fluid concentration from pre-dose values and rate of improvement with the Remote Dielectric Sensing (reds) system. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in urine output, weight, blood tests, and right heart catheterization | — |
Contacts
Public ContactHayato Ohtani
Hamamatsu University School of Medicine
Outcome results
None listed